Business
Business
Latest Headlines
Top Stories
Breaking News
Earnings
Biotech
Investors
Stock Alerts
IPOs
M&A
Canadian
UK
Wallstreet Events
Industry News
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
Economic News
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Cryptocurrency
Crypto
Cryptocurrency
Blockchain
Markets
Markets
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
Politics
US
World
White House
Elections
General News
Forex
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard
Health
Health
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Entertainment
Top Stories
Music news
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium Services
Premium
Intelligent Investor
Biotech Investor
NEW
Login
More
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Business
Corp. News
Latest Headlines
Biotech
Investors
Stock Alerts
IPOs
M&A
Top Stories
Breaking News
Earnings
Canadian
UK
Wallstreet Events
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Crypto
Cryptocurrency
Blockchain
Markets
Market News
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
US
World
White House
Elections
General News
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard
Health
Health News
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Entertainment News
Top Stories
Music News
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium
Intelligent Investor
Biotech Investor
Login
More
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Johnson & Johnson (JNJ)
Johnson & Johnson To Acquire Firefly Bio To Expand Oncology Pipeline
6/8/2026 8:22:32 AM
Johnson & Johnson To Acquire Firefly Bio For $1 Bln In cash
6/8/2026 8:06:02 AM
Weekly Buzz: PHG, KMDA Win FDA Nod; FULC Halts Pociredir; RMD Closes Noctrix Deal; NVS Paces In IgAN
6/5/2026 10:26:20 AM
Johnson & Johnson Reports Phase 2 DAHLIAS Biomarker Data For Nipocalimab In Sjogren's Disease
6/3/2026 6:40:41 AM
Johnson & Johnson Reports Phase 2 DAHLIA Biomarker Data For Nipocalimab In Sjogren's Disease
6/3/2026 2:35:57 AM
JNJ's Nipocalimab Meets Primary Goal In Phase 2 JASMINE Trial Of Systemic Lupus Erythematosus
6/3/2026 2:28:43 AM
Johnson & Johnson: Nipocalimab Phase 2 Study Meets Primary Endpoint In Systemic Lupus Erythematosus Disease Activity
6/3/2026 12:13:50 AM
Johnson & Johnson Presents Positive DAHLIAS Study Biomarker Findings In Adults With Sjögren's Disease
6/3/2026 12:11:41 AM
J&J Phase 1b/2 OrigAMI-4: Subcutaneous Amivantamab Shows 42% ORR In Head & Neck Cancer
5/31/2026 9:37:41 AM
J&J Phase 3 : Apalutamide + Hormone Therapy Before & After Surgery Improves Prostate Cancer Outcomes
5/31/2026 9:27:01 AM
J&J’s Phase 1b/2 OrigAMI-4: Subcutaneous Amivantamab Delivers 42% ORR In Head & Neck Cancer — ASCO 2026
5/31/2026 8:54:08 AM
J&J’s Phase 3 Study: ERLEADA Before & After Surgery Cuts Metastasis/Death Risk In Prostate Cancer
5/31/2026 8:53:30 AM
Johnson & Johnson Reports Promising Phase 1/1b Results In Advanced Lung Cancer
5/29/2026 10:25:23 PM
Weekly Buzz: AZN, JNJ Get FDA Nod; LLY To Acquire Curevo; APGE Advances Zumilokibart
5/29/2026 10:39:40 AM
Johnson & Johnson Reports Positive Data For TECVAYLI As Early As First Relapse In Multiple Myeloma
5/29/2026 9:16:41 AM
Johnson & Johnson Reports TECVAYLI Phase 3 Results With Survival Benefit In Multiple Myeloma
5/29/2026 8:25:30 AM
FDA Approves Expansion Of Johnson & Johnson's TREMFYA In Treating Psoriatic Arthritis Joint Damage
5/29/2026 4:35:17 AM
Johnson & Johnson: FDA Approves Label Expansion For TREMFYA
5/29/2026 1:34:35 AM
FDA Approves Johnson & Johnson’s TREMFYA Label Update For Joint Damage Progression In Psoriatic Arthritis
5/28/2026 10:24:21 PM
Nanobiotix And Johnson & Johnson Report Promising Phase 2 Results For JNJ-1900 In Stage III NSCLC
5/17/2026 10:39:04 AM
1
2
3
Next
»